H. Lundbeck A/S, a leading biopharmaceutical company specialized in brain health, has achieved a significant milestone in expanding advanced migraine care across Asia by announcing today that its new drug application (NDA) for Vyepti® (eptinezumab) has been accepted by the Ministry of Health, Labor and Welfare (MHLW) in Japan. This step is part of a coordinated push extending to regulatory authorities in China and South Korea, supported by compelling Phase 3 SUNRISE trial results confirming Vyepti's preventive efficacy for migraine among Asian patients.

This multi-country regulatory acceptance marks Lundbeck's first step toward securing marketing authorization for Vyepti in these major Asian healthcare markets. If successful, this will be Lundbeck's inaugural product launch in Japan for migraine prevention and the company's first biologic introduction in China and South Korea. The development highlights not only Lundbeck's strategic operational expansion in Asia but also the company's leadership and commitment to addressing a critical unmet need in migraine management for the region, where preventive treatments remain considerably underutilized and the care gap is wide.

In East Asia, migraine presents a notable healthcare challenge, with Japan reporting that 59.4% to 71.8% of migraine sufferers have never consulted a physician regarding their symptoms. In South Korea, figures soar to 75.6%, and in China, clinical diagnosis rates hover around a mere 13.8% of migraine-afflicted adults. These statistics underscore the urgent need to enhance diagnosis, access, and standards of care, especially through the advancement of evidence-based preventive therapies.

The NDA submissions in all three markets are anchored by a robust clinical data package, particularly the SUNRISE Phase 3 trial recently published in Cephalalgia. This multi-regional, randomized, double-blind, placebo-controlled study targeted predominately Asian patients with chronic migraine, exploring both efficacy and safety of eptinezumab. Participants were randomized to receive 100 mg, 300 mg, or placebo by intravenous infusion, and the trial demonstrated not only clinical benefit but also a safety profile in line with global studies, predominantly featuring mild adverse events such as nasopharyngitis and COVID-19 infection.

Upon completion of the SUNRISE trial in Japan, participants were offered entry into the ongoing SUNSET trial, a 60-week open-label extension further evaluating long-term safety and effectiveness. These rigorous studies underpin Lundbeck's regulatory submissions and potential future launches, setting the stage for broader access to migraine preventive care in Asia and benchmarking global standards for chronic headache management.

Migraine is recognized as one of the most prevalent neurological diseases worldwide and a leading source of disability for those under 50. Without effective prevention, repeated attacks can progressively worsen, disrupt personal and professional life, and lead to medication overuse. The anticipated approval and launch of Vyepti will empower clinicians in Asia with new options for patients who have historically suffered from inadequate migraine management, thereby aligning Asian hospital practice with international protocols and innovation.

For hospital administrators, procurement leaders, and clinical directors across Asia, this development is poised to impact formulary decisions, outpatient and neurology service offerings, specialty pharmacy integration, and clinical trial collaboration. Moreover, it offers substantial strategic opportunity for introducing biological therapy infrastructure, process mapping for chronic disease management, and multidisciplinary patient care pathways. The expansion will also inform regional budgets, reimbursement planning, and operational policies aimed at improving patient outcomes through targeted migraine prevention.

Lundbeck's longstanding expertise in neuroscience and its focused innovator strategy, now extended via Vyepti's entry into Asia, is expected to catalyze future migraine and neuro-rare program development. The company is committed to fostering health equity, advancing research, and delivering long-term value to stakeholders. Product launches and expanded access such as Vyepti’s signal a paradigm shift in Asian hospital pharmacy and specialty neurology, moving from episodic symptom management toward structured, preventive care integrated within major hospital systems.

Hospital executives and procurement teams should monitor regulatory progress, potential pricing frameworks, supply chain readiness for biologics, and partnerships with Lundbeck to realize the benefits of next-generation migraine management. The coming months will be pivotal for preparing clinical teams, educating providers, and aligning operational resources for the effective roll-out and adoption of Vyepti across Asian healthcare institutions.